DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]
Clinical data | |
---|---|
Trade names | Clozaprexin |
Other names | Docosahexaenoyl clozapine |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C40H49ClN4O |
Molar mass | 637.31 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]
Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]
References
edit- ^ a b "DHA-clozapine". AdisInsight. Retrieved 17 March 2017.
- ^ Rosack, Jim (4 May 2001). "Targaceuticals Point Way To Developing Safer Drugs". Psychiatric News. 36 (9): 36–37. doi:10.1176/pn.36.9.0036.
- ^ Baldessarini RJ, Campbell A, Webb NL, Swindell CS, Flood JG, Shashoua VE, et al. (January 2001). "Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat". Neuropsychopharmacology. 24 (1): 55–65. doi:10.1016/S0893-133X(00)00173-1. PMID 11106876.